SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announces the initiation of a Phase 2 clinical trial with the Company’s glucagon receptor antagonist LGD-6972 for the ...
Co announces data from a preclinical study on its Selective Androgen Receptor Modulator LGD-3303 at the American Society for Bone and Mineral Research Annual Meeting in Honolulu, Hawaii on Sept 16, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback